Immunological Profile of Silent Brain Infarction and Lacunar Stroke

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Sarchielli, Paola ^a   Nardi, Katiuscia ^a   Chiasserini, Davide ^a   Eusebi, Paolo ^b   Tantucci, Michela ^a   Di Piero, Vittorio ^c   Altieri, Marta ^c   Marini, Carmine ^d   Russo, Tommasina ^d   Silvestrini, Mauro ^e   Paolino, Isabella ^e   Calabresi, Paolo ^a,f   Parnetti, Lucilla ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Regional Health Authority of Umbria   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL9 CHEMOKINE; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR ALPHA; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; SCATTER FACTOR; STEM CELL FACTOR; STEM CELL GROWTH FACTOR BETA; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRAIN INFARCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; IMMUNOLOGICAL PARAMETERS; ITALY; LACUNAR STROKE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

AGED; BIOLOGICAL MARKERS; BRAIN INFARCTION; CELL ADHESION MOLECULES; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; RISK FACTORS; ROC CURVE; STROKE, LACUNAR;

EID: 84879907953     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068428     Document Type: Article

References (62)

1. Zhu Y-C, Dufouil C, Tzourio C, Chabriat H, (2011) Silent brain infarcts: a review of MRI diagnostic criteria. Stroke 42: 1140-1145.
2. Vermeer SE, Longstreth WT, Koudstaal PJ, (2007) Silent brain infarcts: a systematic review. Lancet Neurol 6: 611-619.
3. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, et al. (2003) Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 34: 1126-1129.
4. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, et al. (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348: 1215-1222.
5. Debette S, Beiser A, DeCarli C, Au R, Himali JJ, et al. (2010) Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 41: 600-606.
6. Putaala J, Haapaniemi E, Kurkinen M, Salonen O, Kaste M, et al. (2011) Silent brain infarcts, leukoaraiosis, and long-term prognosis in young ischemic stroke patients. Neurology 76: 1742-1749.
7. Weber R, Weimar C, Wanke I, Moller-Hartmann C, Gizewski ER, et al. (2012) Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy. Stroke 43: 350-355.
8. Fujikawa T, Yamawaki S, Touhouda Y, (1993) Incidence of silent cerebral infarction in patients with major depression. Stroke 24: 1631-1634.
9. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H, et al. (2005) Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke 36: 768-772.
10. Ishikawa J, Tamura Y, Hoshide S, Eguchi K, Ishikawa S, et al. (2007) Low-grade inflammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, wave 1. Stroke 38: 911-917.
11. Bamford JM, (2000) The role of the clinical examination in the subclassification of stroke. Cerebrovasc Dis 10Suppl 4: 2-4.
12. Fisher CM (1998) Lacunes: small, deep cerebral infarcts. 1965. Neurology 50: 841 and 811 pages following.
13. Hosmer D, Lemeshow S (1989) Applied Logistic Regression. New York: John Wiley & Sons. 160-164 p.
14. Drake C, Boutin H, Jones MS, Denes A, McColl BW, et al. (2011) Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun 25: 1113-1122.
15. Antonino MJ, Mahla E, Bliden KP, Tantry US, Gurbel PA, (2009) Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Am J Cardiol 103: 1546-1550.
16. Zhao L, Gray L, Leonardi-Bee J, Weaver CS, Heptinstall S, et al. (2006) Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets 17: 100-104.
17. Husted S, Storey RF, Harrington RA, Emanuelsson H, Cannon CP, (2010) Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol 33: 206-212.
18. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Luscher TF, (2007) Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 12: 113-122.
19. Hoyte LC, Brooks KJ, Nagel S, Akhtar A, Chen R, et al. (2010) Molecular magnetic resonance imaging of acute vascular cell adhesion molecule-1 expression in a mouse model of cerebral ischemia. J Cereb Blood Flow Metab 30: 1178-1187.
20. Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM, (1994) Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 25: 1794-1798.
21. Lindsberg PJ, Carpen O, Paetau A, Karjalainen-Lindsberg ML, Kaste M, (1996) Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation 94: 939-945.
22. Schwab JM, Nguyen TD, Meyermann R, Schluesener HJ, (2001) Human focal cerebral infarctions induce differential lesional interleukin-16 (IL-16) expression confined to infiltrating granulocytes, CD8+ T-lymphocytes and activated microglia/macrophages. J Neuroimmunol 114: 232-241.
23. Wykrzykowska JJ, Garcia-Garcia HM, Goedhart D, Zalewski A, Serruys PW, (2011) Differential protein biomarker expression and their time-course in patients with a spectrum of stable and unstable coronary syndromes in the Integrated Biomarker and Imaging Study-1 (IBIS-1). Int J Cardiol 149: 10-16.
24. Yuen C-M, Chiu C-A, Chang L-T, Liou C-W, Lu C-H, et al. (2007) Level and value of interleukin-18 after acute ischemic stroke. Circ J 71: 1691-1696.
25. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, et al. (2003) Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 108: 2453-2459.
26. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, et al. (2002) Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 106: 24-30.
27. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, et al. (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270: 27348-27357.
28. Correia LCL, Andrade BB, Borges VM, Clarencio J, Bittencourt AP, et al. (2010) Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes. Clin Chim Acta 411: 540-545.
29. Keeley EC, Moorman JR, Liu L, Gimple LW, Lipson LC, et al. (2011) Plasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease. PLoS One 6.
30. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, et al. (1999) Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 104: 1041-1050.
31. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, et al. (2001) Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 89: E41-45.
32. Abramo C, Meijgaarden KE, Garcia D, Franken KL, Klein MR, et al. (2006) Monokine induced by interferon gamma and IFN-gamma response to a fusion protein of Mycobacterium tuberculosis ESAT-6 and CFP-10 in Brazilian tuberculosis patients. Microbes Infect 8: 45-51.
33. Bogoslovsky T, Spatz M, Chaudhry A, Maric D, Luby M, et al. (2011) Stromal-derived factor-1[alpha] correlates with circulating endothelial progenitor cells and with acute lesion volume in stroke patients. Stroke 42: 618-625.
34. Hiraoka A, Sugimura A, Seki T, Nagasawa T, Ohta N, et al. (1997) Cloning, expression, and characterization of a cDNA encoding a novel human growth factor for primitive hematopoietic progenitor cells. Proc Natl Acad Sci U S A 94: 7577-7582.
35. Schirmer SH, van Royen N, Moerland PD, Fledderus JO, Henriques JP, et al. (2009) Local cytokine concentrations and oxygen pressure are related to maturation of the collateral circulation in humans. J Am Coll Cardiol 53: 2141-2147.
36. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, et al. (2007) Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128: 92-105.
37. Haines BA, Mehta SL, Pratt SM, Warden CH, Li PA, (2010) Deletion of mitochondrial uncoupling protein-2 increases ischemic brain damage after transient focal ischemia by altering gene expression patterns and enhancing inflammatory cytokines. J Cereb Blood Flow Metab 30: 1825-1833.
38. Che X, Ye W, Panga L, Wu DC, Yang GY, (2001) Monocyte chemoattractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. Brain Res 902: 171-177.
39. Andres RH, Choi R, Pendharkar AV, Gaeta X, Wang N, et al. (2011) The CCR2/CCL2 interaction mediates the transendothelial recruitment of intravascularly delivered neural stem cells to the ischemic brain. Stroke 42: 2923-2931.
40. Chen Y, Hallenbeck JM, Ruetzler C, Bol D, Thomas K, et al. (2003) Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab 23: 748-755.
41. Strecker J-K, Minnerup J, Gess B, Ringelstein EB, Schabitz W-R, et al. (2011) Monocyte chemoattractant protein-1-deficiency impairs the expression of IL-6, IL-1beta and G-CSF after transient focal ischemia in mice. PLoS One 6.
42. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, et al. (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2: 275-281.
43. Canoui-Poitrine F, Luc G, Mallat Z, Machez E, Bingham A, et al. (2011) Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study. Neurology 77: 1165-1173.
44. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, et al. (2003) Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107: 690-695.
45. Cui X, Chen J, Zacharek A, Li Y, Roberts C, et al. (2007) Nitric oxide donor upregulation of stromal cell-derived factor-1/chemokine (CXC motif) receptor 4 enhances bone marrow stromal cell migration into ischemic brain after stroke. Stem Cells 25: 2777-2785.
46. Dentelli P, Del Sorbo L, Rosso A, Molinar A, Garbarino G, et al. (1999) Human IL-3 stimulates endothelial cell motility and promotes in vivo new vessel formation. J Immunol 163: 2151-2159.
47. Doeppner TR, Kaltwasser B, ElAli A, Zechariah A, Hermann DM, et al. (2011) Acute hepatocyte growth factor treatment induces long-term neuroprotection and stroke recovery via mechanisms involving neural precursor cell proliferation and differentiation. J Cereb Blood Flow Metab 31: 1251-1262.
48. Rajpathak SN, Wang T, Wassertheil-Smoller S, Strickler HD, Kaplan RC, et al. (2010) Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the Women's Health Initiative. Stroke 41: 857-862.
49. Anan F, Masaki T, Jikumaru K, Iwao T, Eshima N, et al. (2010) Hepatocyte growth factor is a significant risk factor for white matter lesions in Japanese type 2 diabetic patients. Eur J Clin Invest 40: 585-590.
50. Okada Y, Copeland BR, Mori E, Tung MM, Thomas WS, et al. (1994) P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 25: 202-211.
51. Konoeda F, Shichita T, Yoshida H, Sugiyama Y, Muto G, et al. (2010) Therapeutic effect of IL-12/23 and their signaling pathway blockade on brain ischemia model. Biochem Biophys Res Commun 402: 500-506.
52. Mangino M, Braund P, Singh R, Steeds R, Stevens S, et al. (2008) Association analysis of IL-12B and IL-23R polymorphisms in myocardial infarction. J Mol Med (Berl) 86: 99-9103.
53. Momiyama Y, Ohmori R, Nagano M, Kato R, Taniguchi H, et al. (2005) Polymorphism of the 3′-untranslated region of interleukin-12 p40 gene is not associated with the presence or severity of coronary artery disease. Circ J 69: 793-797.
54. Yang L, Zhang Z, Sun D, Xu Z, Zhang X, et al. (2010) The serum interleukin-18 is a potential marker for development of post-stroke depression. Neurol Res 32: 340-346.
55. Welsh P, Lowe GDO, Chalmers J, Campbell DJ, Rumley A, et al. (2008) Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke 39: 2226-2230.
56. Lambertsen KL, Gregersen R, Meldgaard M, Clausen BH, Heibol EK, et al. (2004) A role for interferon-gamma in focal cerebral ischemia in mice. J Neuropathol Exp Neurol 63: 942-955.
57. Inacio AR, Ruscher K, Leng L, Bucala R, Deierborg T, (2011) Macrophage migration inhibitory factor promotes cell death and aggravates neurologic deficits after experimental stroke. J Cereb Blood Flow Metab 31: 1093-1106.
58. Lin SG, Yu XY, Chen YX, Huang XR, Metz C, et al. (2000) De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res 87: 1202-1208.
59. Wang L, Zis O, Ma G, Shan Z, Zhang X, et al. (2009) Upregulation of macrophage migration inhibitory factor gene expression in stroke. Stroke 40: 973-976.
60. Saino O, Taguchi A, Nakagomi T, Nakano-Doi A, Kashiwamura S-I, et al. (2010) Immunodeficiency reduces neural stem/progenitor cell apoptosis and enhances neurogenesis in the cerebral cortex after stroke. J Neurosci Res 88: 2385-2397.
61. Vogelgesang A, May VEL, Grunwald U, Bakkeboe M, Langner S, et al. (2010) Functional status of peripheral blood T-cells in ischemic stroke patients. PLoS One 5.
62. Cui M, Wang L, Liang X, Ma X, Liu Y, et al. (2010) Blocking TRAIL-DR5 signaling with soluble DR5 reduces delayed neuronal damage after transient global cerebral ischemia. Neurobiol Dis 39: 138-147.